Long-term outcomes by lobular versus ductal histology in four NSABP adjuvant breast cancer trials.

ABSTRACT

We evaluated differences in long-term outcomes of invasive lobular carcinoma (ILC) vs breast cancers of no special type (NST) treated with anthracycline-based adjuvant chemotherapy using 4 National Surgical Adjuvant Breast and Bowel Project (NSABP) randomized phase III trials (B-22, B-25, B-28, B-30). Our cohort included 11,251 patients with NST and 1,231 with ILC. Patients with ILC were older, had larger and more often estrogen receptor-positive tumors, and more positive lymph nodes. During early follow-up (0-5 years), patients with ILC had fewer recurrences (HR 0.797; 95% confidence interval [CI] 0.685-0.929) and deaths (HR 0.756; 95% CI 0.623-0.917). After 5 years patients with ILC had more recurrences (HR 1.30; 95% CI 1.085-1.558) and deaths (HR 1.044; 95% CI 0.898-1.214). Conditional probability analysis showed significant interactions between time-period and histologic type for recurrences (p < .001) and deaths (p < .001). Patients with ILC have elevated risk of late recurrence and death compared to patients with NST.